Press

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

Oct 26 • 3 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D. M.B.A, Vice President of R&D, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. Silo Pharma is a sponsor of the three-day conference being…

Aion Therapeutic Provides Default Status Update

Oct 25 • 2 min read

Aion Therapeutic Inc. (CSE: AION) announces that further to its press releases of September 13, 2022, September 26, 2022 and October 11, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203”). On August 30, 2022,…

Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities

Oct 25 • 3 min read

Core One Labs Inc. (CSE:COOL | OTCQB:CLABF | Frankfurt:LD6, WKN:A3CSSU) is pleased to announce, as a follow up to the Company’s press release dated March 20, 2022, wherein the Company announced that it was actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies, that the Company’s Board of Directors is…

Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations

Oct 25 • 3 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announces that its wholly-owned subsidiary Awakn Oslo AS has entered into a debt financing agreement with TD Veen AS , a…

Silo Pharma – Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions

Oct 25 • 2 min read

October 24, 2022 Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438